• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Cytokinetics Unveils Aficamten Data at ESC Congress 2025

    GLOBENEWSWIRE

    Cytokinetics` Drug Effective for Heart Symptoms than Std of Care

    REUTERS

    Cytokinetics to Participate in September Investor Conferences

    GLOBENEWSWIRE

    Cytokinetics Reveals Five Aficamten Presentations at ESC Congress

    GLOBENEWSWIRE

    Cytokinetics Appoints Jim Daly to Director Board

    GLOBENEWSWIRE

    Cytokinetics Grants Inducements Under Nasdaq Rule 5635(c)(4)

    GLOBENEWSWIRE

    Cytokinetics Reports Q2 2025 Financials, Updates on Business

    GLOBENEWSWIRE

    Cytokinetics Announces Q2 Results on August 7, 2025

    GLOBENEWSWIRE

    Cytokinetics grants inducements under Nasdaq Listing Rule

    GLOBENEWSWIRE

    Cytokinetics Unveils Five Aficamten Presentations at 2025

    GLOBENEWSWIRE

    Cytokinetics Announces Inducement Grants for Nasdaq Listing Rule

    GLOBENEWSWIRE

    Cytokinetics Calls for Annual Corporate Giving Proposals

    GLOBENEWSWIRE

    Cytokinetics at Jefferies Global Healthcare Conference

    GLOBENEWSWIRE

    Cytokinetics Presents Data on Aficamten at ESC Heart Failure 2025

    GLOBENEWSWIRE

    Cytokinetics Announces Inducement Grants Under Nasdaq Rule

    GLOBENEWSWIRE

    Cytokinetics Hosts Symposium on Muscle Biology Landscape

    GLOBENEWSWIRE

    Cytokinetics Announces Positive Topline Results From MAPLE-HCM

    GLOBENEWSWIRE

    Cytokinetics to Present at ESC Heart Failure 2025 Congress

    GLOBENEWSWIRE

    Cytokinetics to Hold Annual Meeting of Stockholders

    GLOBENEWSWIRE

    Cytokinetics Reports Q1 2025 Financial Results and Business Update

    GLOBENEWSWIRE

    Cytokinetics Announces New PDUFA Date for Aficamten

    GLOBENEWSWIRE

    Cytokinetics to Participate in May Investor Conferences

    GLOBENEWSWIRE

    Cytokinetics to Announce First Quarter Results on May 6, 2025

    GLOBENEWSWIRE

    Cytokinetics Announces Inducement Grants Under Nasdaq LR 5635(c)(4)

    GLOBENEWSWIRE

    Cytokinetics at 24th Annual Needham Virtual Healthcare Conference

    GLOBENEWSWIRE

    Cytokinetics Launches EARTH-HCM for Hypertrophic Cardiomyopathy

    GLOBENEWSWIRE

    Cytokinetics Announces Inducement Grants Under Nasdaq Rule

    GLOBENEWSWIRE

    Cytokinetics Announces 5 Presentations at ACC Annual Session

    GLOBENEWSWIRE

    Cytokinetics Announces Five Presentations at ACC Annual Session

    GLOBENEWSWIRE

    Cytokinetics to Participate in March Investor Conferences

    GLOBENEWSWIRE

    Cytokinetics Reports Q4 2024 Financial Results and Update

    GLOBENEWSWIRE

    Cytokinetics Announces Inducement Grants Under Nasdaq Rule

    GLOBENEWSWIRE

    Cytokinetics to Announce Q4 Results on February 27, 2025

    GLOBENEWSWIRE

    Cytokinetics Names Robert E. Landry to Board of Directors

    GLOBENEWSWIRE

    Cytokinetics to Participate in Oppenheimer Annual Health Conference

    GLOBENEWSWIRE

    Cytokinetics Announces Inducement Grants Under Nasdaq LR 5635(c)(4)

    GLOBENEWSWIRE

    Cytokinetics Announces Recipients of Communications Grant Program

    GLOBENEWSWIRE

    Cytokinetics Begins AMBER-HFpEF Trial For Heart Failure Patients

    GLOBENEWSWIRE

    Cytokinetics Announces 2025 Corporate Milestones and Vision 2030

    GLOBENEWSWIRE

    Cytokinetics to Present at the 43rd Annual J.P. Morgan Conference

    GLOBENEWSWIRE

    Cytokinetics Announce Inducement Grants Under Nasdaq LR 5635(C)(4)

    GLOBENEWSWIRE

    Cytokinetics Announces EMA Validation for Aficamten in HCM

    GLOBENEWSWIRE

    Sanofi scoops up China rights to Cytokinetics’ heart disease med

    FIERCE BIOTECH

    Cytokinetics Announces Sanofi Acquired Aficamten Rights in China

    GLOBENEWSWIRE

    Cytokinetics Starts Comet-HF Ph 3 Trial for Heart Failure Treatment

    GLOBENEWSWIRE

    Cytokinetics Announces Inducement Grant Under Nasdaq LR 5635(c)(4)

    GLOBENEWSWIRE

    Cytokinetics to Participate in December Investor Conferences

    GLOBENEWSWIRE

    Bayer acquires rights to Cytokinetics` heart drug in Japan

    REUTERS

    Cytokinetics Presents Aficamten Data in Hypertrophic Cardiomyopathy

    GLOBENEWSWIRE

    Cytokinetics Presents GALACTIC-HF Data at AHA 2024

    GLOBENEWSWIRE

    Cytokinetics to Participate in the 2024 Jefferies London Conference

    GLOBENEWSWIRE

    Cytokinetics Announces Initiation of Ph 1 Clinical of CK-4015089

    GLOBENEWSWIRE

    Cytokinetics Reports Q3 2024 Financial Results

    GLOBENEWSWIRE

    Cytokinetics Announces Six Presentations at AHA Scientific Sessions

    GLOBENEWSWIRE

    Cytokinetics Reports Inducement Grants Under Nasdaq LR5635(c)(4)

    GLOBENEWSWIRE

    Cytokinetics to Announce Third Quarter Results on November 6, 2024

    GLOBENEWSWIRE

    Cytokinetics Highlights Cardiac Myosin Modulation Progress

    GLOBENEWSWIRE

    Cytokinetics Announces Grants Under Nasdaq Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    Cytokinetics to Host Investor & Analyst Day on October 16, 2024

    GLOBENEWSWIRE

    Cytokinetics Presents SEQUOIA-HCM Data At HFSA Annual Meeting

    GLOBENEWSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.